Zynerba Pharmaceuticals Inc (ZYNE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zynerba Pharmaceuticals Inc (ZYNE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8064
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company provides pipeline product candidates such as ZYN002 and ZYN001. Its ZYN002 is a synthetic CBD, a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery. Zynerba Pharmaceuticals’s ZYN001 is a pro-drug of THC which enables the transdermal delivery through skin and into the circulatory system via patch. The company’s pipeline candidates target various indications which include refractory focal epilepsy, fragile x syndrome, developmental and epileptic encephalopathies, fibromyalgia and peripheral neuropathic pain, among others. Zynerba Pharmaceuticals is headquartered in Devon, Pennsylvania, the US.

Zynerba Pharmaceuticals Inc (ZYNE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Zynerba Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Zynerba Pharma Raises USD13 Million in Venture Financing 11
Partnerships 12
Zynerba Pharma Partners with Lohmann Therapie-Systeme 12
Licensing Agreements 13
Zynerba Pharma Enters into Patent Assignment Agreement with Albany College of Pharmacy 13
Equity Offering 14
Zynerba Pharma Prices Public Offering of Shares for USD32.5 Million 14
Zynerba Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 16
Zynerba Pharma Raises USD48.3 Million in IPO 18
Zynerba Pharmaceuticals Inc – Key Competitors 20
Zynerba Pharmaceuticals Inc – Key Employees 21
Zynerba Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Aug 02, 2018: Zynerba Pharmaceuticals reports second quarter 2018 financial results and operational highlights 23
May 08, 2018: Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights 25
Mar 12, 2018: Zynerba Pharmaceuticals Announces Fourth Quarter and Year End 2017 Financial Results 27
Nov 14, 2017: Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights 29
Aug 01, 2017: Zynerba Pharmaceuticals Reports Second Quarter 2017 Financial Results and Operational Highlights 32
May 09, 2017: Zynerba Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Highlights 34
Mar 27, 2017: Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Operational Highlights 36
Corporate Communications 38
Apr 16, 2018: Zynerba Pharmaceuticals Names John P. Butler To Board of Directors 38
Jan 03, 2018: Zynerba Pharmaceuticals announces Appointment of new Chief Medical Officer 39
Clinical Trials 40
Jan 03, 2017: Zynerba Pharmaceuticals Announces Initiation of the FAB-C Exploratory Phase 2 Clinical Trial of ZYN002 CBD Gel in Patients with Fragile X Syndrome 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zynerba Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Zynerba Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zynerba Pharma Raises USD13 Million in Venture Financing 11
Zynerba Pharma Partners with Lohmann Therapie-Systeme 12
Zynerba Pharma Enters into Patent Assignment Agreement with Albany College of Pharmacy 13
Zynerba Pharma Prices Public Offering of Shares for USD32.5 Million 14
Zynerba Pharma Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 16
Zynerba Pharma Raises USD48.3 Million in IPO 18
Zynerba Pharmaceuticals Inc, Key Competitors 20
Zynerba Pharmaceuticals Inc, Key Employees 21
Zynerba Pharmaceuticals Inc, Subsidiaries 22

List of Figures
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Zynerba Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Zynerba Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Zynerba Pharmaceuticals Inc (ZYNE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cardiovascular Systems Inc (CSII):医療機器:M&Aディール及び事業提携情報
    Summary Cardiovascular Systems Inc (CSI) is a medical device company that develops and commercializes products for the treatment of peripheral and coronary vascular disease. The company's products include peripheral orbital atherectomy system, coronary orbital atherectomy system, crowns, and accesso …
  • BHP:企業の戦略・SWOT・財務情報
    BHP - Strategy, SWOT and Corporate Finance Report Summary BHP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing …
  • Biomatrica Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Biomatrica Inc (Biomatrica) is a developer, manufacturer, and supplier of stability technologies preserve biological materials. The company offers DNA, RNA, proteins, cells, and entire assays for diagnostics, research, forensics, biobanks, and sustainability applications. Its products includ …
  • China Steel Corporation:企業の戦略・SWOT・財務情報
    China Steel Corporation - Strategy, SWOT and Corporate Finance Report Summary China Steel Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Shree Renuka Sugars Ltd (RENUKA):企業の財務・戦略的SWOT分析
    Shree Renuka Sugars Ltd (RENUKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Mckinsey & Company, Inc.:企業の戦略・SWOT・財務分析
    Mckinsey & Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary Mckinsey & Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Deyaar Development:企業の戦略・SWOT・財務情報
    Deyaar Development - Strategy, SWOT and Corporate Finance Report Summary Deyaar Development - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Alliancebernstein Holding Lp
    Alliancebernstein Holding Lp - Strategy, SWOT and Corporate Finance Report Summary Alliancebernstein Holding Lp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Japan Logistics Fund, Inc. :企業の戦略・SWOT・財務情報
    Japan Logistics Fund, Inc. - Strategy, SWOT and Corporate Finance Report Summary Japan Logistics Fund, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • KAZ Minerals PLC:企業の戦略・SWOT・財務情報
    KAZ Minerals PLC - Strategy, SWOT and Corporate Finance Report Summary KAZ Minerals PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Narada Power Source Co Ltd (300068):企業の財務・戦略的SWOT分析
    Summary Narada Power Source Co Ltd (Narada Power) is a battery manufacturer and distributor that markets and supplies stored energy solutions. The company's products include eos series batteries, acme series, acmeG series, GP series, TTG series, TT series, eosG series, GPG series, MP series, HRL ser …
  • PharmaCyte Biotech Inc (PMCB)-製薬・医療分野:企業M&A・提携分析
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company’s technology is used for the treatment of advanced and inoperable pancreatic cancer, and diabetes. It develops …
  • Exelon Generation Company LLC:発電所・企業SWOT分析
    Exelon Generation Company LLC - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析
    Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • bioMerieux Inc-医療機器分野:企業M&A・提携分析
    Summary bioMerieux Inc (bioMerieux), a subsidiary of Institut Merieux SA is a provider of diagnostic solutions. The company offers its products for clinical solutions which include blood culture, cancer diagnostics, cardiovascular disease, cardiovascular pathology, clinical laboratories, companion d …
  • Baytex Energy Corp (BTE):企業の財務・戦略的SWOT分析
    Baytex Energy Corp (BTE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • ING Life Insurance Company Korea, Ltd.:企業の戦略・SWOT・財務情報
    ING Life Insurance Company Korea, Ltd. - Strategy, SWOT and Corporate Finance Report Summary ING Life Insurance Company Korea, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Automotive Holdings Group Limited:企業のM&A・事業提携・投資動向
    Automotive Holdings Group Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Automotive Holdings Group Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Singapore Technologies Aerospace Ltd.:企業の戦略・SWOT・財務情報
    Singapore Technologies Aerospace Ltd. - Strategy, SWOT and Corporate Finance Report Summary Singapore Technologies Aerospace Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Revance Therapeutics Inc (RVNC):企業の財務・戦略的SWOT分析
    Revance Therapeutics Inc (RVNC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆